| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory for Molecular Brain Research [R. M., M. T., M. N., C-L. Z.] and Department of Neurosurgery [Y. S., H. A.], Hokkaido University School of Medicine, Sapporo 060, Japan
The mdm2 oncogene encodes a 90-kDa nuclear phosphoprotein that binds and inhibits the function of the p53 tumor suppressor protein. It was recently reported that the expression of alternatively spliced variants of mdm2 correlated with malignancy in ovarian tumors and bladder carcinomas. We analyzed the presence of alternatively spliced mdm2 variants and studied their correlation to p53 status in a total of 66 human astrocytic tumors, including 32 glioblastomas multiforme, 17 anaplastic astrocytomas, 12 astrocytomas, and 5 pilocytic astrocytomas, using a specific nested reverse transcription-PCR technique. The full-length mdm2 transcript was demonstrated in all of the cases. Multiple-sized PCR products were found in 29 cases. Two of 5 pilocytic astrocytomas (40%), none of 12 astrocytomas, and 5 of 17 anaplastic astrocytomas (29%) showed alternative splice variants. In contrast, 22 of 32 glioblastomas (69%) showed the presence of splice variants, demonstrating a significantly higher frequency than in lower-grade astrocytomas (P < 0.0003). A majority of the splice variants were 707 base-type (mdm2-b), which was confirmed by sequence analysis. There was no apparent correlation of the presence of mdm2 splice variants with p53 gene status. These results suggest a new role for mdm2, independent of p53 gene status, as an oncogene in the development of malignant astrocytic tumors.
1 To whom requests for reprints should be addressed, at Laboratory for Molecular Brain Research, Department of Neurosurgery, Hokkaido University School of Medicine, North-15 West-7, Kita-Ku, Sapporo 060, Japan. Phone: 81-11-716-1161; Fax: 81-11-706-7878; E-mail: m_tada@med.hokudai.ac.jp.
Received 12/ 1/97. Accepted 1/ 6/98.
This article has been cited by other articles:
|
|
 |
|
  K. Schuster, L. Fan, and L. C. Harris MDM2 Splice Variants Predominantly Localize to the Nucleoplasm Mediated by a COOH-Terminal Nuclear Localization Signal Mol. Cancer Res., April 1, 2007; 5(4): 403 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Venables Aberrant and Alternative Splicing in Cancer Cancer Res., November 1, 2004; 64(21): 7647 - 7654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Steinman, E. Burstein, C. Lengner, J. Gosselin, G. Pihan, C. S. Duckett, and S. N. Jones An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis J. Biol. Chem., February 6, 2004; 279(6): 4877 - 4886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bartel, L. C. Harris, P. Wurl, and H. Taubert MDM2 and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides Mol. Cancer Res., January 1, 2004; 2(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Fridman, E. Hernando, M. T. Hemann, E. de Stanchina, C. Cordon-Cardo, and S. W. Lowe Tumor Promotion by Mdm2 Splice Variants Unable to Bind p53 Cancer Res., September 15, 2003; 63(18): 5703 - 5706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bartl, J. Ban, H. Weninger, G. Jug, and H. Kovar A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene Nucleic Acids Res., February 15, 2003; 31(4): 1136 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dang, M.-L. Kuo, C. M. Eischen, L. Stepanova, C. J. Sherr, and M. F. Roussel The RING Domain of Mdm2 Can Inhibit Cell Proliferation Cancer Res., February 1, 2002; 62(4): 1222 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Garcia, R. Villuendas, M. Sanchez-Beato, A. Sanchez-Aguilera, L. Sanchez, I. Prieto, and M. A. Piris Nucleolar p14ARF Overexpression in Reed-Sternberg Cells in Hodgkin's Lymphoma : Absence of p14ARF/Hdm2 Complexes Is Associated with Expression of Alternatively Spliced Hdm2 Transcripts Am. J. Pathol., February 1, 2002; 160(2): 569 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, L. Nan, D. Yu, S. Agrawal, and R. Zhang Antisense Anti-MDM2 Oligonucleotides As a Novel Therapeutic Approach to Human Breast Cancer: In Vitro and in Vivo Activities and Mechanisms Clin. Cancer Res., November 1, 2001; 7(11): 3613 - 3624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lukas, D.-Q. Gao, M. Keshmeshian, W.-H. Wen, D. Tsao-Wei, S. Rosenberg, and M. F. Press Alternative and Aberrant Messenger RNA Splicing of the mdm2 Oncogene in Invasive Breast Cancer Cancer Res., April 1, 2001; 61(7): 3212 - 3219. [Abstract] [Full Text]
|
|
|
|
|
|
Y. F. M. Ramos, R. Stad, J. Attema, L. T. C. Peltenburg, A. J. van der Eb, and A. G. Jochemsen Aberrant Expression of HDMX Proteins in Tumor Cells Correlates with Wild-Type p53 Cancer Res., March 1, 2001; 61(5): 1839 - 1842. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Kleihues and H. Ohgaki Phenotype vs Genotype in the Evolution of Astrocytic Brain Tumors Toxicol Pathol, January 1, 2000; 28(1): 164 - 170. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Kleihues and H. Ohgaki Primary and secondary glioblastomas: From concept to clinical diagnosis Neuro-oncol, January 1, 1999; 1(1): 44 - 51. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
